Biovitrum, which carries out Pharmacia's Swedish research into metabolic disorders, is to become independent.
Pharmacia will therefore have no basic research activities remaining in Sweden.
External investors, with Nordic Capital and MPM Capital at the helm, are buying two thirds of Biovitrum for SKR 1 bn.
The purchasers will inject SKR 800 M of capital into Biovitrum and will acquire shares from Pharmacia for SKR 200 M.
In addition, the consortium has undertaken to make a further SKR 400 M available to Biovitrum when it …